FibroGen Misses In First Of Two Pivotal DMD Trials
Executive Summary
The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.
You may also be interested in...
Five Clinical Trial Misses Of 2023
The biopharma industry’s fate lies largely in its R&D success and failures. Here, Scrip looks at five clinical trial failures that got readers clicking in 2023. Some were more comprehensive than others, highlighting the nuance that can be injected into clinical data in different settings and subgroups.
FibroGen Adrift After Yet Another Pamrevlumab Failure
The asset appears to have a similar future in Duchenne muscular dystrophy as it has in idiopathic pulmonary fibrosis – to wit, none.
FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF
Months after a disappointment in Duchenne muscular dystrophy, the US firm’s pamrevlumab has missed the mark in a pivotal idiopathic pulmonary fibrosis trial, boding poorly for other trials and forcing the firm to enter cost-cutting mode.